Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 15Nivolumab 9atezolizumab 5Ipilimumab 4Drug Therapy 4Docetaxel 4Radiotherapy 3Radiosurgery 3Paclitaxel 3Gemcitabine 3Cetuximab 3Carboplatin 3Blood Specimen Collection 3temsirolimus 2spartalizumab 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2entinostat 2durvalumab 2belinostat 2Sirolimus 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Metformin 2Irinotecan 2Fluorouracil 2Etoposide 2Dexamethasone 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Blood Cell Count × Thoracic × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡